CLCA4

Summary

CLCA4 (chloride channel accessory 4, HGNC:2018) is a protein-coding gene on chromosome 1p22.3, encoding Calcium-activated chloride channel regulator 4 (Q14CN2). May be involved in mediating calcium-activated chloride conductance.

The protein encoded by this gene belongs to the calcium sensitive chloride conductance protein family. To date, all members of this gene family map to the same site on chromosome 1p31-p22 and share high degrees of homology in size, sequence and predicted structure, but differ significantly in their tissue distributions. Alternative splicing results in multiple transcript variants, only one of which is thought to be protein coding.

Source: NCBI Gene 22802 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cystic fibrosis (Supportive, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 138 total
• Phenotypes (HPO): 35
• Druggable target: yes
• MANE Select transcript: NM_012128

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2018
Approved symbol	CLCA4
Name	chloride channel accessory 4
Location	1p22.3
Locus type	gene with protein product
Status	Approved
Aliases	CaCC2
Ensembl gene	ENSG00000016602
Ensembl biotype	protein_coding
OMIM	616857
Entrez	22802

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 13 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000370563, ENST00000496322, ENST00000862139, ENST00000862140, ENST00000862141, ENST00000862142, ENST00000862143, ENST00000862144, ENST00000967246, ENST00000967247, ENST00000967248, ENST00000967249, ENST00000967250, ENST00000967251

RefSeq mRNA: 1 — MANE Select: NM_012128 NM_012128

CCDS: CCDS41355

Canonical transcript exons

ENST00000370563 — 14 exons

Exon	Start	End
ENSE00000776087	86565274	86565451
ENSE00000776089	86567424	86567651
ENSE00000776090	86571077	86571254
ENSE00000776091	86572614	86572720
ENSE00000776092	86574540	86574755
ENSE00000776093	86575332	86575599
ENSE00000776094	86577902	86578072
ENSE00000776095	86579354	86579587
ENSE00001851400	86579942	86580754
ENSE00001942194	86547078	86547278
ENSE00003470195	86565802	86566020
ENSE00003518290	86560211	86560358
ENSE00003643983	86563661	86563769
ENSE00003653245	86559932	86560072

Expression profiles

Bgee: expression breadth ubiquitous, 209 present calls, max score 99.41.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.5397 / max 826.8079, expressed in 108 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
3862	1.0280	39
3865	0.2183	65
3864	0.1829	58
3863	0.0502	35
3866	0.0386	22
3861	0.0217	10

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.41	gold quality
colonic mucosa	UBERON:0000317	99.27	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.14	gold quality
oral cavity	UBERON:0000167	98.93	gold quality
esophagus squamous epithelium	UBERON:0006920	98.54	gold quality
pharyngeal mucosa	UBERON:0000355	98.30	gold quality
esophagus mucosa	UBERON:0002469	97.94	gold quality
rectum	UBERON:0001052	97.86	gold quality
epithelium of esophagus	UBERON:0001976	97.86	gold quality
mucosa of transverse colon	UBERON:0004991	97.21	gold quality
cervix epithelium	UBERON:0004801	95.94	gold quality
squamous epithelium	UBERON:0006914	94.40	gold quality
mucosa of urinary bladder	UBERON:0001259	94.16	gold quality
ileal mucosa	UBERON:0000331	93.96	gold quality
nasal cavity epithelium	UBERON:0005384	92.55	gold quality
cervix squamous epithelium	UBERON:0006922	92.32	gold quality
buccal mucosa cell	CL:0002336	91.54	gold quality
mammalian vulva	UBERON:0000997	90.76	gold quality
transverse colon	UBERON:0001157	89.67	gold quality
upper leg skin	UBERON:0004262	89.61	gold quality
gingiva	UBERON:0001828	89.40	gold quality
body of tongue	UBERON:0011876	88.68	gold quality
periodontal ligament	UBERON:0008266	87.26	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	86.85	gold quality
tongue squamous epithelium	UBERON:0006919	86.79	gold quality
vermiform appendix	UBERON:0001154	86.71	gold quality
vagina	UBERON:0000996	86.46	gold quality
nasal cavity mucosa	UBERON:0001826	86.44	gold quality
gingival epithelium	UBERON:0001949	86.32	gold quality
upper arm skin	UBERON:0004263	83.75	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9543	yes	2845.00
E-CURD-114	yes	54.29
E-ANND-3	yes	14.98

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting CLCA4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-3659	99.70	67.97	694
HSA-MIR-4699-5P	98.99	67.50	1210
HSA-MIR-367-5P	98.84	67.18	902
HSA-MIR-501-5P	98.77	68.88	1328
HSA-MIR-4635	98.74	67.63	1339
HSA-MIR-5187-5P	98.54	67.94	952
HSA-MIR-6728-5P	97.79	66.33	891
HSA-MIR-643	97.35	67.91	805
HSA-MIR-362-5P	95.87	66.02	554
HSA-MIR-500B-5P	95.87	66.04	557
HSA-MIR-4330	95.44	66.39	993

Literature-anchored findings (GeneRIF, showing 9)

• CLCA1 and CLCA4 may have roles as modulators of the gastrointestinal basic defect in cystic fibrosis (PMID:15490240)
• CLCA4 modulates the capability to express residual chloride secretion in colonic tissue. (PMID:23073314)
• CLCA4 and CLCA2 play complementary but distinct roles in epithelial differentiation (PMID:24386311)
• CLCA4 contributes to migration and invasion by suppressing epithelial-mesenchymal transition via PI3K/ATK signaling and predicts favourable prognosis for hepatocellular carcinoma. (PMID:30312171)
• Six SNPs, c.390C>T (rs190628533), c.1474A>G (rs2231599), c.2105C>G (rs757773924), c.2371A>T) (rs759981524), c.956G>A (rs763334876), and c.895T>C (rs79822589) were identified in the study group of cases in Non-Obstructive Azoospermia but not in control subjects. The allele and genotype frequencies of the six SNPs were not significantly different between the study group and the controls. (PMID:30887952)
• CLCA4 inhibits migration and invasion by suppressing EMT via PI3K/ATK signaling and predicts favorable prognosis of CRC which may help to distinguish potential risk of lymph node metastasis in CRC. (PMID:31164625)
• Frameshift Mutations and Loss of Expression of CLCA4 Gene are Frequent in Colorectal Cancers With Microsatellite Instability. (PMID:32773719)
• CLCA4 and MS4A12 as the significant gene biomarkers of primary colorectal cancer. (PMID:32797167)
• Modulation of TMEM16B channel activity by the calcium-activated chloride channel regulator 4 (CLCA4) in human cells. (PMID:38825009)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Clca4a	ENSMUSG00000068547
mus_musculus	Clca4b	ENSMUSG00000074195
rattus_norvegicus	Clca4	ENSRNOG00000029889

Paralogs (2): CLCA1 (ENSG00000016490), CLCA2 (ENSG00000137975)

Protein

Protein identifiers

Calcium-activated chloride channel regulator 4 — Q14CN2 (reviewed: Q14CN2)

Alternative names: Calcium-activated chloride channel family member 4, Calcium-activated chloride channel protein 2, Chloride channel accessory 4

All UniProt accessions (1): Q14CN2

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in mediating calcium-activated chloride conductance.

Subcellular location. Cell membrane. Apical cell membrane. Secreted.

Tissue specificity. Primarily expressed in the digestive tract, mainly in colon. Detected in smaller amounts in brain, urogenital organs, testis, and salivary and mammary glands. Highly expressed in the epithelial layer and submucosal gland of the inferior turbinate mucosa. Lower levels in the epithelial layer of nasal polyp.

Post-translational modifications. The translation product is autoproteolytically cleaved by the metalloprotease domain in the endoplasmic reticulum into a N-terminal and a C-terminal products that remain physically associated with each other. The cleavage is necessary for calcium-activated chloride channel (CaCC) activation activity.

Domain organisation. The metalloprotease region is responsible for autoproteolytic processing. It can also cross-cleave other CLCA substrates.

Induction. Down-regulated in oral tongue squamous cell carcinomas.

Similarity. Belongs to the CLCR family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14CN2-1	1	yes
Q14CN2-2	2

RefSeq proteins (1): NP_036260* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002035	VWF_A	Domain
IPR004727	CLCA_chordata	Family
IPR013642	CLCA_N	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036465	vWFA_dom_sf	Homologous_superfamily
IPR051266	CLCR	Family

Pfam: PF00092, PF08434

UniProt features (32 total): glycosylation site 10, sequence variant 5, chain 3, binding site 3, splice variant 3, region of interest 2, signal peptide 1, site 1, sequence conflict 1, transmembrane region 1, domain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14CN2-F1	89.48	0.76

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 697–698 (cleavage; by autolysis); 156

Ligand- & substrate-binding residues (3): 159; 166; 155

Glycosylation sites (10): 75, 340, 504, 542, 588, 628, 811, 832, 837, 852

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2672351	Stimuli-sensing channels

MSigDB gene sets: 169 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GSE45365_NK_CELL_VS_CD8A_DC_DN, GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_INORGANIC_ANION_TRANSPORT, GOBP_CHLORIDE_TRANSPORT, KEGG_OLFACTORY_TRANSDUCTION, GOCC_APICAL_PLASMA_MEMBRANE, SABATES_COLORECTAL_ADENOMA_DN, chr1p22, GOBP_TRANSMEMBRANE_TRANSPORT, GOCC_APICAL_PART_OF_CELL, GOBP_PROTEOLYSIS, GOCC_PLASMA_MEMBRANE_REGION, GOMF_GATED_CHANNEL_ACTIVITY, GOMF_PASSIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY

GO Biological Process (4): proteolysis (GO:0006508), monoatomic ion transmembrane transport (GO:0034220), chloride transport (GO:0006821), chloride transmembrane transport (GO:1902476)

GO Molecular Function (7): metalloendopeptidase activity (GO:0004222), intracellularly calcium-gated chloride channel activity (GO:0005229), chloride channel activity (GO:0005254), metal ion binding (GO:0046872), peptidase activity (GO:0008233), metallopeptidase activity (GO:0008237), hydrolase activity (GO:0016787)

GO Cellular Component (4): extracellular region (GO:0005576), plasma membrane (GO:0005886), apical plasma membrane (GO:0016324), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Ion channel transport	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein metabolic process	1
monoatomic ion transport	1
transmembrane transport	1
monoatomic anion transport	1
inorganic anion transport	1
chloride transport	1
monoatomic anion transmembrane transport	1
endopeptidase activity	1
metallopeptidase activity	1
chloride channel activity	1
ligand-gated monoatomic anion channel activity	1
intracellularly calcium-gated channel activity	1
monoatomic anion channel activity	1
chloride transmembrane transporter activity	1
cation binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
membrane	1
cell periphery	1
apical part of cell	1
plasma membrane region	1

Protein interactions and networks

STRING

1498 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CLCA4	ANO2	Q9NQ90	984
CLCA4	ANO1	Q5XXA6	946
CLCA4	CFTR	P13569	720
CLCA4	ANO6	Q4KMQ2	655
CLCA4	MS4A12	Q9NXJ0	624
CLCA4	ANO10	Q9NW15	605
CLCA4	BEST1	O76090	590
CLCA4	BEST2	Q8NFU1	589
CLCA4	GUCA2A	Q02747	571
CLCA4	ZG16	O60844	555
CLCA4	ANO5	Q75V66	527
CLCA4	LRRC8B	Q6P9F7	514
CLCA4	SLC26A3	P40879	489
CLCA4	SLC12A2	P55011	484
CLCA4	LRRC8A	Q8IWT6	480
CLCA4	ANO7	Q6IWH7	480

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CLCA4	BDKRB2	psi-mi:“MI:0915”(physical association)	0.370
SRRT	A2ML1	psi-mi:“MI:0914”(association)	0.350
INSR	RIMOC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (24): CLCA4 (Two-hybrid), FKBP7 (Two-hybrid), PANX1 (Two-hybrid), SLC39A7 (Two-hybrid), ELOVL4 (Two-hybrid), FAM209A (Two-hybrid), ERGIC3 (Two-hybrid), GPR42 (Two-hybrid), SLC22A23 (Two-hybrid), FAM134C (Two-hybrid), MGST3 (Two-hybrid), FCER1G (Two-hybrid), SLC39A2 (Two-hybrid), SCN3B (Two-hybrid), AQP2 (Two-hybrid)

ESM2 similar proteins: A0A2D0TC04, A1A4K5, A2VDP5, A8K7I4, J3SBP3, J3SEZ3, O14638, P06802, P0DQQ4, P15396, P18563, P18564, P22413, P54793, P97259, P97675, Q08834, Q09328, Q13822, Q14CN2, Q1RPR6, Q29444, Q2TU62, Q32KH8, Q3SZI1, Q4FZV0, Q5FYA8, Q5GF25, Q5R5M5, Q64610, Q6AYF4, Q6DDW2, Q6DYE8, Q6NXH2, Q6PT52, Q6Q473, Q863C4, Q8BTJ4, Q8K1B9, Q8K2I4

Diamond homologs: A8K7I4, P54281, Q14CN2, Q2TU62, Q6PT52, Q6Q473, Q8BG22, Q9D7Z6, Q9QX15, Q9TUB5, Q9UQC9, Q55874

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

138 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	120
Likely benign	14
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1891 predictions. Top by Δscore:

Variant	Effect	Δscore
1:86547275:AGAGG:A	donor_loss	1.0000
1:86547276:GAG:G	donor_gain	1.0000
1:86547277:AGGTA:A	donor_loss	1.0000
1:86547278:GGTAA:G	donor_loss	1.0000
1:86547279:G:GC	donor_loss	1.0000
1:86547279:G:GG	donor_gain	1.0000
1:86547280:T:A	donor_loss	1.0000
1:86560068:AACAT:A	donor_gain	1.0000
1:86560069:ACAT:A	donor_gain	1.0000
1:86560070:CAT:C	donor_gain	1.0000
1:86560073:G:GG	donor_gain	1.0000
1:86563742:C:G	donor_gain	1.0000
1:86565452:G:GG	donor_gain	1.0000
1:86570455:A:AG	donor_gain	1.0000
1:86570455:A:G	donor_gain	1.0000
1:86571072:T:TA	acceptor_gain	1.0000
1:86571072:TGCA:T	acceptor_loss	1.0000
1:86571075:A:AG	acceptor_gain	1.0000
1:86571075:A:AT	acceptor_loss	1.0000
1:86571075:AG:A	acceptor_gain	1.0000
1:86571075:AGGT:A	acceptor_gain	1.0000
1:86571076:G:GA	acceptor_gain	1.0000
1:86571076:GG:G	acceptor_gain	1.0000
1:86571076:GGT:G	acceptor_gain	1.0000
1:86571076:GGTG:G	acceptor_gain	1.0000
1:86571076:GGTGA:G	acceptor_gain	1.0000
1:86571250:AACAG:A	donor_loss	1.0000
1:86571251:ACAGG:A	donor_loss	1.0000
1:86571252:CAGGT:C	donor_loss	1.0000
1:86571253:AGGT:A	donor_loss	1.0000

AlphaMissense

6103 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:86563681:T:A	W157R	0.992
1:86563681:T:C	W157R	0.992
1:86579551:T:A	W774R	0.991
1:86579551:T:C	W774R	0.991
1:86567514:T:C	F349L	0.988
1:86567516:T:A	F349L	0.988
1:86567516:T:G	F349L	0.988
1:86563696:T:A	W162R	0.987
1:86563696:T:C	W162R	0.987
1:86580124:A:C	S847R	0.982
1:86580126:T:A	S847R	0.982
1:86580126:T:G	S847R	0.982
1:86565383:T:A	C223S	0.980
1:86565384:G:C	C223S	0.980
1:86567502:G:T	G345W	0.980
1:86575540:C:A	A631D	0.979
1:86559947:G:C	A59P	0.976
1:86563698:G:C	W162C	0.974
1:86563698:G:T	W162C	0.974
1:86565389:T:C	F225L	0.974
1:86565391:C:A	F225L	0.974
1:86565391:C:G	F225L	0.974
1:86565865:T:A	C267S	0.974
1:86565866:G:C	C267S	0.974
1:86567454:G:C	A329P	0.974
1:86565988:T:C	C308R	0.972
1:86575341:T:A	W565R	0.972
1:86575341:T:C	W565R	0.972
1:86579553:G:C	W774C	0.972
1:86579553:G:T	W774C	0.972

dbSNP variants (sampled 300 via entrez): RS1000064671 (1:86572631 G>A), RS1000091891 (1:86562168 G>A), RS1000372816 (1:86568561 A>C), RS1000580072 (1:86578501 T>C), RS1000744372 (1:86551673 C>G), RS1000937677 (1:86577187 C>T), RS1000947334 (1:86545344 A>G,T), RS1001074542 (1:86574647 T>G), RS1001162334 (1:86551123 A>G), RS1001357985 (1:86575004 C>T), RS1001644931 (1:86548133 A>G), RS1001668850 (1:86562350 T>C), RS1001875446 (1:86568169 T>C), RS1001943973 (1:86556073 A>G), RS1001952583 (1:86562940 A>G,T)

Disease associations

OMIM: gene MIM:616857 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Disease	Classification	Inheritance
cystic fibrosis	Supportive	Autosomal recessive

Mondo (3): autism (MONDO:0005260), male infertility (MONDO:0005372), cystic fibrosis (MONDO:0009061)

Orphanet (0):

HPO phenotypes

35 total (30 of 35 shown, HPO-id order):

HPO	Term
HP:0000246	Sinusitis
HP:0000365	Hearing impairment
HP:0000716	Depression
HP:0000739	Anxiety
HP:0000787	Nephrolithiasis
HP:0000938	Osteopenia
HP:0000939	Osteoporosis
HP:0001392	Abnormality of the liver
HP:0001394	Cirrhosis
HP:0001508	Failure to thrive
HP:0001738	Exocrine pancreatic insufficiency
HP:0002020	Gastroesophageal reflux
HP:0002024	Malabsorption
HP:0002035	Rectal prolapse
HP:0002099	Asthma
HP:0002105	Hemoptysis
HP:0002107	Pneumothorax
HP:0002110	Bronchiectasis
HP:0002205	Recurrent respiratory infections
HP:0002570	Steatorrhea
HP:0002724	Recurrent Aspergillus infections
HP:0002726	Recurrent Staphylococcus aureus infections
HP:0002783	Recurrent lower respiratory tract infections
HP:0002842	Recurrent Burkholderia cepacia infections
HP:0002910	Elevated circulating hepatic transaminase concentration
HP:0003251	Male infertility
HP:0004401	Meconium ileus
HP:0005376	Recurrent Haemophilus influenzae infections
HP:0006536	Airway obstruction
HP:0012236	Elevated sweat chloride

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST012047_20	Fasting glucose	4.000000e-07

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500
D003550	Cystic Fibrosis	C06.689.202; C08.381.187; C16.320.190; C16.614.213
D007248	Infertility, Male	C12.100.500.430; C12.100.750.700; C12.200.294.430

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2364708 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression, increases abundance, increases expression	3
Tobacco Smoke Pollution	affects expression, increases expression	2
bisphenol A	increases methylation	1
sodium arsenate	increases abundance, decreases expression	1
arsenite	increases abundance, decreases expression	1
monomethylarsonic acid	decreases expression	1
arsenic acid	decreases expression, increases abundance	1
hydroquinone	decreases expression	1
monomethylarsonous acid	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
dimethylmonothioarsinic acid	decreases expression	1
Vehicle Emissions	increases expression, decreases reaction	1
Cacodylic Acid	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Nickel	decreases expression	1
Progesterone	affects cotreatment, decreases expression	1
Silicon Dioxide	decreases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1
Particulate Matter	decreases reaction, increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_YA38	IDG-HEK293T-CLCA4-V5-OE	Transformed cell line	Female

Clinical trials (associated diseases)

600 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00157690	PHASE4	COMPLETED	Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
NCT00208078	PHASE4	TERMINATED	Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.
NCT00244270	PHASE4	COMPLETED	Cystic Fibrosis and Totally Implantable Vascular Access Devices
NCT00333385	PHASE4	TERMINATED	Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
NCT00411736	PHASE4	COMPLETED	Scandinavian Cystic Fibrosis Azithromycin Study
NCT00418470	PHASE4	TERMINATED	Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People
NCT00431964	PHASE4	COMPLETED	Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa
NCT00434278	PHASE4	TERMINATED	A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
NCT00483769	PHASE4	COMPLETED	One Year Glargine Treatment in CFRD Children and Adolescents
NCT00528190	PHASE4	COMPLETED	Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
NCT00557089	PHASE4	COMPLETED	The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
NCT00572975	PHASE4	COMPLETED	Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea
NCT00680316	PHASE4	TERMINATED	A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis
NCT00685035	PHASE4	COMPLETED	Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings
NCT00744250	PHASE4	TERMINATED	Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control
NCT00787917	PHASE4	TERMINATED	An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
NCT00843817	PHASE4	COMPLETED	RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
NCT00890370	PHASE4	COMPLETED	Should Any One Airway Clearance Technique be Recommended for People With Cystic Fibrosis?
NCT00996424	PHASE4	TERMINATED	The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function
NCT01044719	PHASE4	UNKNOWN	Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
NCT01100606	PHASE4	COMPLETED	A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age
NCT01131507	PHASE4	COMPLETED	PR-018: An Open-Label, Safety Extension of Study PR-011
NCT01207245	PHASE4	COMPLETED	Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis
NCT01323101	PHASE4	COMPLETED	Doxycycline Effects on Inflammation in Cystic Fibrosis
NCT01327703	PHASE4	COMPLETED	Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
NCT01377792	PHASE4	COMPLETED	Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis
NCT01400750	PHASE4	COMPLETED	Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis
NCT01429259	PHASE4	COMPLETED	Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
NCT01608555	PHASE4	COMPLETED	Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis
NCT01667094	PHASE4	UNKNOWN	A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
NCT01694069	PHASE4	TERMINATED	Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
NCT01702415	PHASE4	WITHDRAWN	Zoledronic Acid in Cystic Fibrosis
NCT01712334	PHASE4	COMPLETED	A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis
NCT01737983	PHASE4	COMPLETED	Effect of Lactobacillus Reuteri in Cystic Fibrosis
NCT01844778	PHASE4	COMPLETED	Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
NCT01880346	PHASE4	COMPLETED	Comparison of Absorption of Vitamin D in Cystic Fibrosis
NCT01882400	PHASE4	COMPLETED	Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
NCT01937325	PHASE4	UNKNOWN	CPET in CF Patients With One G551D Mutation Taking VX770
NCT02015663	PHASE4	TERMINATED	Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
NCT02048592	PHASE4	UNKNOWN	Impact of Immunonutrition on the Patients With Cystic Fibrosis